Kenzaburo Yamaji, Sadahiro Iwabuchi, Yuko Tokunaga, Shinichi Hashimoto, Daisuke Yamane, Sakiko Toyama, Risa Kono, Bouchra Kitab, Kyoko Tsukiyama-Kohara, Yosuke Osawa, et al. Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023. 166. 115379-115379
Yui Mukade, Sayaka Kobayashi, Yoshimi Nishijima, Kiminori Kimura, Akira Watanabe, Hayato Ikota, Ken Shirabe, Hideaki Yokoo, Masanao Saio. Phosphotungstic Acid-treated Picrosirius Red Staining Improves Whole-slide Quantitative Analysis of Collagen in Histological Specimens. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2022. 221554221141140-221554221141140
Masamichi Kimura, Eiichi Ogawa, Kenichi Harada, Jun Imamura, Masanao Saio, Yoshihiro Ikura, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Ichiro Ieiri, et al. Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study. BMJ open gastroenterology. 2022. 9. 1
Masamichi Kimura, Koji Nishikawa, Yosuke Osawa, Jun Imamura, Kenzaburo Yamaji, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Atsushi Tanaka, et al. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease. Hepatology communications. 2022. 6. 10. 2732-2747
Kiminori Kimura, Tatsuya Kanto, Shinji Shimoda, Kenichi Harada, Masamichi Kimura, Koji Nishikawa, Jun Imamura, Eiichi Ogawa, Masanao Saio, Yoshihiro Ikura, et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. eBioMedicine. 2022. 80. 104069-104069
Masamichi Kimura, Koji Nishikawa, Jun Imamura, Keni-chi Harada, Masashi Mizokami, Kiminori Kimura. Safety, tolerability, and anti-fibrotic effect of PRI-724, a CBP/beta-catenin inhibitor, in patients with hepatitis C virus cirrhosis: A single-center, open-label, dose escalation phase 1 trial. HEPATOLOGY. 2017. 66. 6. 1262A-1262A
Yohei Mano, Sachiyo Yoshio, Hirotaka Shoji, Masaya Sugiyama, Hiroyoshi Doi, Toru Okamoto, Yosuke Osawa, Kiminori Kimura, Tomoharu Yoshizumi, Ken Shirabe, et al. Critical roles of bone morphogenetic protein 4 in cirrhotic and cancer-associated fibroblasts that regulates cellar senescence and cancer-supportive phenotype in the human liver. HEPATOLOGY. 2016. 64. 86A-86A
Kiminori Kimura, Kenichi Harada, Takuji Okusaka, Kazuaki Inoue, Shinji Shimoda, Tatsuya Kanto, Masashi Mizokami. Single-Centre, Dose Escalation, Open-Label Phase 1 Trial of the experimental anti-fibrotic small molecule PRI-724 in Patients with Hepatitis C virus related Cirrhosis. HEPATOLOGY. 2016. 64. 41A-42A
Hirotaka Shoji, Sachiyo Yoshio, Yohei Mano, Masaya Sugiyama, Yoshihiko Aoki, Norio Itokawa, Masanori Atsukawa, Yosuke Osawa, Kiminori Kimura, Akinobu Taketomi, et al. Pro-angiogenic Tie2-expressing monocytes/TEMs as a biomarker of the response to sorafenib in patients with advanced hepatocellular carcinoma. HEPATOLOGY. 2015. 62. 449A-449A